Showing 6201-6210 of 7769 results for "".
- VTAMA (Tapinarof) Cream, 1% Shows Efficacy in Patients With Intertriginous Plaque Psoriasishttps://practicaldermatology.com/news/vtama-tapinarof-cream-1/2462085/VTAMA (tapinarof) Cream, 1% performed well in intertriginous plaque psoriasis (iPsO), according to new Phase 4 data presented at the 43rd Annual Fall Clinical Dermatology Conference in Las Vegas. This Phase 4 study expands the body of data for VTAMA cream in adult plaque
- Delgocitinib Cream Soothes Moderate to Severe Chronic Hand Eczemahttps://practicaldermatology.com/news/delgocitinib-cream-soothes-moderate-to-severe-chronic-hand-eczema/2462071/Delgocitinib cream produced statistically significant improvements in both patient- and clinician-reported efficacy outcomes in adults with moderate to severe chronic hand eczema (CHE) compared to cream vehicle, according to results from the DELTA 2 trial presented at the European Academy of Derm
- Roflumilast Foam 0.3% Eases Scalp Itch in as Early as 24 hourshttps://practicaldermatology.com/news/roflumilast-foam-03-eases-scalp-itch-in-as-early-as-24-hours/2462068/Arcutis’ roflumilast foam 0.3% demonstrated significant improvements in both scalp and body psoriasis across all efficacy endpoints when compared to vehicle, according to patient-reported outcome data from the pivotal ARRECTOR Phase 3 trial in scalp and body psoriasis presented at the
- Study: Melanoma No Longer the Leading Cause of Skin Cancer Deathshttps://practicaldermatology.com/news/study-melanoma-no-longer-the-leading-cause-of-skin-cancer-deaths/2462062/Non-melanoma skin cancer (NMSC) is causing a greater number of global deaths than melanoma, according to a new study presented at the European Academy of Dermatology and Venerology (EADV) Congress 2023 in Berlin, Germany. Researchers also believe that NMSC is underreported and that the
- EADV News: Continued Treatment with Opzelura (Ruxolitinib) Cream Shows Efficacy in Nonsegmental Vitiligohttps://practicaldermatology.com/news/eadv-news-continued-treatment-with-opzelura-ruxolitinib-cream-shows-efficacy-in-nonsegmental-vitiligo/2462059/Nonsegmental vitiligo patients who initially experienced limited or no facial or total body repigmentation at six months achieved improved repigmentation after continued treatment with Opzelura (Ruxolitinib) Cream for up to two years, according to new results of a pooled analysis of long-term ext
- Positive Phase 2a Data Shown for MC2-32, a Novel HSP90 Inhibitor in HShttps://practicaldermatology.com/news/positive-phase-2a-data-shown-for-mc2-32-a-novel-hsp90-inhibitor-in-hs/2462058/MC2-32 (previously RGRN-305), a first-in-class, oral therapy HSP90 inhibitor, performed well in Hidradenitis Suppurativa (HS), according to Phase 2a results presented during a late-breaking session at the European Academy of Dermatology and Venereology (EADV) Annual Meeting in Berlin.
- InMode: Employees in Isreal Are Safehttps://practicaldermatology.com/news/inmode-employees-in-isreal-are-safe/2462053/InMode Ltd. has affirmed the safety of the employees at the Company's Yokneam, Israel headquarters and does not anticipate any interruption in productionas a result of the Israel-Hamas War, "InMode is committed to supporting all customers, distributors, employees, and
- DecisionDx-Melanoma Outperforms MSKCC Nomogram in Predicting Sentinel Lymph Node Positivity in Melanomahttps://practicaldermatology.com/news/decisiondx-melanoma-outperforms-mskcc-nomogram-in-predicting-sentinel-lymph-node-positivity-in-melanoma/2462044/Castle Biosciences, Inc.’s DecisionDx-Melanoma outperformed a nomogram developed at the Memorial Sloan Kettering Cancer Center (MSKCC) in predicting the risk of sentinel lymph node (SLN) positivity in patients with cutaneous melanoma (CM), according to a new study in
- Regenerative Medicine Breakthrough: Researchers Create BioPrinted Full Thickness Skinhttps://practicaldermatology.com/news/regenerative-medicine-breakthrough-researchers-create-bioprinted-full-thickness-skin/2462041/New bioprinted skin may accelerate wound healing, support healthy extracellular matrix remodeling, and aid in complete wound recovery, according to research out of the Wake Forest Institute for Regenerative Medicine (WFIRM). Available grafts are often temporary, or if permanent, h
- Revealed: Key Genes That May Up Nodular Melanoma Riskhttps://practicaldermatology.com/news/revealed-key-genes-that-may-up-nodular-melanoma-risk/2462038/New research sheds light on gene variants which may contribute to higher risk for nodular melanoma. Nodular melanoma accounts for around 14% of invasive melanoma cases, but the aggressive subtype is the largest contributor to melanoma deaths. “Nodular melanoma is often detect